Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

NCT07581808 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hypercholesterolemia
Atherosclerotic Cardiovascular Disease (ASCVD)

Interventions

DRUG: Inclisiran
DRUG: Alirocumab

Sponsor

University Medical Centre Ljubljana